Is Cara Therapeutics Inc (CARA) a Leader in the Biotechnology Industry?

The 58 rating InvestorsObserver gives to Cara Therapeutics Inc (CARA) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 88 percent of stocks in the Biotechnology industry, CARA’s 58 overall rating means the stock scores better than 58 percent of all stocks.

CARA has an Overall Score of 58. Find out what this means to you and get the rest of the rankings on CARA!

See Full CARA Report

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. InvestorsObserver allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 58 would rank higher than 58 percent of all stocks. These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Cara Therapeutics Inc Stock Today?

Cara Therapeutics Inc (CARA) stock is lower by -1.72% while the S&P 500 has gained 1.51% as of 3:37 PM on Monday, Nov 29. CARA has fallen -$0.22 from the previous closing price of $12.80 on volume of 330,832 shares. Over the past year the S&P 500 is higher by 28.78% while CARA has fallen -14.25%. CARA earned $0.44 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 28.62. Click Here to get the full Stock Report for Cara Therapeutics Inc stock.